首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   118903篇
  免费   7702篇
  国内免费   452篇
耳鼻咽喉   1621篇
儿科学   3241篇
妇产科学   2168篇
基础医学   14171篇
口腔科学   2694篇
临床医学   11645篇
内科学   24440篇
皮肤病学   1834篇
神经病学   11572篇
特种医学   4969篇
外国民族医学   11篇
外科学   19404篇
综合类   1432篇
一般理论   132篇
预防医学   9870篇
眼科学   2567篇
药学   7412篇
中国医学   180篇
肿瘤学   7694篇
  2023年   535篇
  2022年   812篇
  2021年   2562篇
  2020年   1523篇
  2019年   2341篇
  2018年   2743篇
  2017年   2059篇
  2016年   2232篇
  2015年   2510篇
  2014年   3709篇
  2013年   5209篇
  2012年   7882篇
  2011年   8263篇
  2010年   4588篇
  2009年   4120篇
  2008年   7430篇
  2007年   7792篇
  2006年   7611篇
  2005年   7517篇
  2004年   7066篇
  2003年   6656篇
  2002年   6253篇
  2001年   1169篇
  2000年   1046篇
  1999年   1261篇
  1998年   1327篇
  1997年   1120篇
  1996年   1003篇
  1995年   913篇
  1994年   823篇
  1993年   713篇
  1992年   745篇
  1991年   712篇
  1990年   617篇
  1989年   613篇
  1988年   579篇
  1987年   573篇
  1986年   557篇
  1985年   666篇
  1984年   744篇
  1983年   658篇
  1982年   846篇
  1981年   785篇
  1980年   718篇
  1979年   436篇
  1978年   507篇
  1977年   460篇
  1976年   379篇
  1975年   395篇
  1974年   365篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study...  相似文献   
3.
4.
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs.  相似文献   
5.
6.
7.
8.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号